Our Science
OUR SCIENCE
Congress Presentations
This section includes posters and presentations related to Arvinas’ PROTAC science, discovery compounds, and clinical-stage assets presented at scientific congresses in the past three years.
SOHO 2025 | Houston, TX
Sep 3 - 6, 2025
Poster
Phase 1 Study of ARV-393, a PROTAC BCL6 Degrader, in Advanced Non-Hodgkin LymphomaSOHO 2025 | Houston, TX
Sep 3 - 6, 2025
Poster
ARV-393, a PROTAC BCL6 Degrader, Combined With Biologics or Small-Molecule Inhibitors Induces Tumor Regressions in Diffuse Large B-Cell Lymphoma ModelsSOHO 2025 | Houston, TX
Sep 3 - 6, 2025
Poster
ARV-393, a PROTAC BCL6 Degrader, in Preclinical Models of Diffuse Large B-cell Lymphoma, Nodal T-Follicular Helper Cell Lymphoma, and Transformed Follicular LymphomaICML 2025 | Lugano, Switzerland
Jun 17 - 21, 2025
Poster
ARV-393, a PROteolysis TArgeting Chimera (PROTAC) BCL6 Degrader, Combined With Biologics or Small-Molecule Inhibitors Induces Tumor Regressions in Diffuse Large B-Cell Lymphoma ModelsEHA 2025 | Milan, Italy
Jun 12 - 15, 2025
Poster
ARV-393, a PROteolysis TArgeting Chimera (PROTAC) BCL6 Degrader, is Efficacious in Preclinical Models of Diffuse Large B-Cell Lymphoma, Nodal T-Follicular Helper Cell Lymphoma, and Transformed Follicular LymphomaASCO 2025 | Chicago, IL
May 30 - Jun 3, 2025
Presentation
Vepdegestrant, a PROTAC Estrogen Receptor (ER) Degrader, vs Fulvestrant in ER-Positive/Human Epidermal Growth Factor Receptor 2 (HER2)–Negative Advanced Breast Cancer: Results of the Global, Randomized, Phase 3 VERITAC-2 StudyASCPT 2025 | Washington, DC
May 28 - 31, 2025
Poster
The Effect of Carbamazepine on the Pharmacokinetics of Vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) Estrogen Receptor Degrader, in Healthy AdultsIAPRD 2025 | New York City, NY
May 7 - 10, 2025
Poster
First-in-Human Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of ARV-102, a PROTAC LRRK2 Degrader, in Healthy VolunteersAACR 2025 | Chicago, IL
Apr 25 - 30, 2025